肾脏替代治疗与抗生素剂量对重症患者抗生素浓度的影响:多国采样研究
这项前瞻性多国药代动力学研究在14国29个ICU纳入381例接受肾脏替代治疗(RRT)的重症患者,采集508份抗生素谷浓度。结果显示RRT处方、抗生素剂量及估算肾脏清除率变异大,美罗培南、哌拉西林和他唑巴坦、万古霉素谷浓度常未达治疗目标。
要点
- 重症RRT患者抗生素剂量、RRT处方及估算肾功能变异达4-8倍。
- 估算总肾脏清除率越高,美罗培南、哌拉西林、万古霉素谷浓度越低。
- 万古霉素谷浓度未达下限比例高达55%,哌拉西林未达上限达36%。
核心结论
- 重症RRT患者抗生素剂量、RRT处方及估算总肾脏清除率变异显著,导致抗生素浓度高度变异,许多患者未达治疗目标。
研究设计与样本
- 前瞻性、观察性、多国药代动力学研究,来自14个国家29个ICU,纳入381例患者,采集508份谷浓度。
主要发现
- 抗生素剂量、RRT处方及估算内生肾功能变异达4-8倍。
- 总体估算总肾脏清除率中位数50 mL/min(IQR 35-65),较高估算总肾脏清除率与所有抗生素较低谷浓度相关(P < .05)。
- 美罗培南谷浓度中位数12.1 mg/L(IQR 7.9-18.8),哌拉西林78.6 mg/L(IQR 49.5-127.3),他唑巴坦9.5 mg/L(IQR 6.3-14.2),万古霉素14.3 mg/L(IQR 11.6-21.8)。
- 美罗培南、哌拉西林、万古霉素谷浓度未达最佳上限者分别占26%、36%、72%,未达最佳下限者分别占4%、4%、55%。
关键数值与推荐
- 美罗培南谷浓度未达最佳上限26%、下限4%;哌拉西林未达上限36%、下限4%;万古霉素未达上限72%、下限55%。
临床怎么用
- 对接受RRT的重症患者,应关注抗生素剂量与RRT处方差异,并考虑估算总肾脏清除率对谷浓度的影响,必要时监测谷浓度以优化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal dosing of antibiotics in critically ill patients receiving renal replacement therapy (RRT) remains unclear. In this study, we describe the variability in RRT techniques and antibiotic dosing in critically ill patients receiving RRT and relate observed trough antibiotic concentrations to optimal targets. METHODS: We performed a prospective, observational, multinational, pharmacokinetic study in 29 intensive care units from 14 countries. We collected demographic, clinical, and RRT data. We measured trough antibiotic concentrations of meropenem, piperacillin-tazobactam, and vancomycin and related them to high- and low-target trough concentrations. RESULTS: We studied 381 patients and obtained 508 trough antibiotic concentrations. There was wide variability (4-8-fold) in antibiotic dosing regimens, RRT prescription, and estimated endogenous renal function. The overall median estimated total renal clearance (eTRCL) was 50 mL/minute (interquartile range [IQR], 35-65) and higher eTRCL was associated with lower trough concentrations for all antibiotics (P < .05). The median (IQR) trough concentration for meropenem was 12.1 mg/L (7.9-18.8), piperacillin was 78.6 mg/L (49.5-127.3), tazobactam was 9.5 mg/L (6.3-14.2), and vancomycin was 14.3 mg/L (11.6-21.8). Trough concentrations failed to meet optimal higher limits in 26%, 36%, and 72% and optimal lower limits in 4%, 4%, and 55% of patients for meropenem, piperacillin, and vancomycin, respectively. CONCLUSIONS: In critically ill patients treated with RRT, antibiotic dosing regimens, RRT prescription, and eTRCL varied markedly and resulted in highly variable antibiotic concentrations that failed to meet therapeutic targets in many patients.
引用
- Roberts JA, Joynt GM, Lee A, et al. The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. Clin Infect Dis. 2021. PMID: 32150603. doi:10.1093/cid/ciaa224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。